Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-31
DOI
10.3389/fimmu.2021.718621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity
- (2021) Ke Xu et al. SCIENCE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
- (2021) Lu Tang et al. Biomed Research International
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset
- (2020) Enrique Zudaire et al. BLOOD
- Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
- (2020) Rachael M. Zemek et al. Frontiers in Immunology
- Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells
- (2020) Connor J. Dwyer et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
- (2020) Sonia Guedan et al. JOURNAL OF CLINICAL INVESTIGATION
- A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.
- (2020) Angela Tatiana Alistar et al. JOURNAL OF CLINICAL ONCOLOGY
- Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
- (2020) Jesus G. Berdeja et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
- (2020) Troels Holz Borch et al. Journal for ImmunoTherapy of Cancer
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
- (2020) Xiangyu Zhao et al. Molecular Therapy-Oncolytics
- MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects
- (2020) Vivek Verma et al. NATURE IMMUNOLOGY
- Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
- (2019) Giuseppe Curigliano et al. DRUG SAFETY
- Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer
- (2019) Angela Esposito et al. JAMA Oncology
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review
- (2019) Jianxiang Zhang et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- CAR-T efficacy: is conditioning the key?
- (2019) Sattva S. Neelapu BLOOD
- Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy
- (2019) Jaco A. C. van Bruggen et al. BLOOD
- Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence
- (2019) Sneha Ramakrishna et al. CLINICAL CANCER RESEARCH
- Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.
- (2019) Timothy A Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
- (2019) Amir A. Jazaeri et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
- (2019) Dongxu Wang et al. Journal of Hematology & Oncology
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Treg cells in cancer immunotherapy
- (2019) Atsushi Tanaka et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
- (2019) Chelsea Kotch et al. Expert Review of Clinical Immunology
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
- (2019) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
- (2019) Sherly Mardiana et al. Science Translational Medicine
- Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
- (2019) Shin Hye Yoo et al. Scientific Reports
- State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
- (2019) Richard Lemal et al. Journal for ImmunoTherapy of Cancer
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression
- (2019) Sanjay Chandrasekaran et al. MOLECULAR CANCER RESEARCH
- Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma
- (2019) Zhitao Ying et al. Molecular Therapy-Oncolytics
- Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
- (2019) U Dafni et al. ANNALS OF ONCOLOGY
- Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
- (2019) Xinjie Xu et al. Frontiers in Immunology
- PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
- (2019) Franziska E. Marquard et al. BIOCHEMICAL PHARMACOLOGY
- Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
- (2019) Yangjing Zhao et al. Cellular & Molecular Immunology
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- GMP CAR-T cell production
- (2018) Adrian P. Gee BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- T cell senescence and CAR-T cell exhaustion in hematological malignancies
- (2018) Dimitri Kasakovski et al. Journal of Hematology & Oncology
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- The functions and regulation of the PTEN tumour suppressor: new modes and prospects
- (2018) Yu-Ru Lee et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials
- (2018) Xuan Li et al. PLoS One
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer
- (2018) Qiongshu Li et al. Oncology Letters
- A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).
- (2018) Rom S. Leidner et al. JOURNAL OF CLINICAL ONCOLOGY
- In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas
- (2018) Carlos A. Ramos et al. MOLECULAR THERAPY
- Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function
- (2018) Jennifer L. Cannons et al. Frontiers in Immunology
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report
- (2018) Christopher Funk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
- (2018) Maartje W. Rohaan et al. Journal for ImmunoTherapy of Cancer
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
- (2018) Saman Maleki Vareki Journal for ImmunoTherapy of Cancer
- Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer
- (2018) Xinge Shi et al. Journal of Bone Oncology
- Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia
- (2017) Hima V. Vangapandu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
- (2017) Daniel T. Harris et al. JOURNAL OF IMMUNOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet
- (2017) P.E. Bunney et al. PHYSIOLOGY & BEHAVIOR
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection
- (2017) Marcia Bellon et al. Viruses-Basel
- Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
- (2017) Mayuko Uehara et al. Nature Communications
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses
- (2017) Nikolaos Patsoukis et al. Frontiers in Immunology
- PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
- (2017) Jacob S. Bowers et al. Frontiers in Immunology
- Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
- (2017) Louise A. Elliott et al. Frontiers in Immunology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
- (2016) P. Vuylsteke et al. ANNALS OF ONCOLOGY
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
- (2016) Jiqing Sai et al. CLINICAL CANCER RESEARCH
- Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
- (2016) M. Sade-Feldman et al. CLINICAL CANCER RESEARCH
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- CD4+T cell effector commitment coupled to self-renewal by asymmetric cell divisions
- (2016) Simone A. Nish et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/ BRAF -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor
- (2016) Hélène Bonnevaux et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
- (2016) Cristian Massacesi et al. OncoTargets and Therapy
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Macrophage PI3K Drives Pancreatic Ductal Adenocarcinoma Progression
- (2016) M. M. Kaneda et al. Cancer Discovery
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells
- (2016) Godehard Scholz et al. EBioMedicine
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
- (2016) Vita Golubovskaya et al. Cancers
- Idelalisib-associated Enterocolitis
- (2015) Christine Y. Louie et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives
- (2015) Martina Sanlorenzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
- (2015) Cyrille J. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy
- (2015) Christopher A. Klebanoff et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
- (2015) Stefano Ugel et al. JOURNAL OF CLINICAL INVESTIGATION
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
- (2015) M.H. Geukes Foppen et al. Molecular Oncology
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Prolonged overall survival in gastric cancer patients after adoptive immunotherapy
- (2015) Guo-Qing Zhang WORLD JOURNAL OF GASTROENTEROLOGY
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma
- (2015) Rikke Andersen et al. Human Vaccines & Immunotherapeutics
- Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
- (2014) Vandana G. Abramson et al. BREAST CANCER RESEARCH AND TREATMENT
- Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
- (2014) J. G. Crompton et al. CANCER RESEARCH
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
- (2014) Peter J. Murray et al. IMMUNITY
- Myeloid-derived suppressor cells in malignant melanoma
- (2014) Viktor Umansky et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile
- (2014) E. Sierra-Filardi et al. JOURNAL OF IMMUNOLOGY
- A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
- (2014) Shweta Joshi et al. MOLECULAR CANCER RESEARCH
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- Two Birds with One Stone: Dual p110δ and p110γ Inhibition
- (2013) Klaus Okkenhaug CHEMISTRY & BIOLOGY
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
- (2013) M. J. Besser et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
- (2013) Thomas F Gajewski et al. CURRENT OPINION IN IMMUNOLOGY
- The who's who of T-cell differentiation: Human memory T-cell subsets
- (2013) Yolanda D. Mahnke et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- AMPKα1: A glucose sensor that controls CD8 T-cell memory
- (2013) Julia Rolf et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
- (2013) Michael C. Jensen et al. IMMUNOLOGICAL REVIEWS
- IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
- (2013) Geok Choo Sim et al. JOURNAL OF CLINICAL INVESTIGATION
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency
- (2013) Carrie L Lucas et al. NATURE IMMUNOLOGY
- PI3K in cancer–stroma interactions: bad in seed and ugly in soil
- (2013) E Hirsch et al. ONCOGENE
- Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery
- (2012) Arian Sadeghi et al. ACTA ONCOLOGICA
- PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
- (2012) Lomon So et al. BIOCHEMICAL JOURNAL
- Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
- (2012) Richard Wu et al. CANCER JOURNAL
- Metabolic switching and fuel choice during T-cell differentiation and memory development
- (2012) Gerritje J. W. Windt et al. IMMUNOLOGICAL REVIEWS
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+T cells
- (2012) David K. Finlay et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- Tumor-Infiltrating Lymphocytes in Melanoma
- (2012) Sylvia Lee et al. Current Oncology Reports
- GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
- (2012) Ines M. Macias-Perez et al. Current Hematologic Malignancy Reports
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
- (2011) A. M. Lesokhin et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- An Interleukin-21- Interleukin-10-STAT3 Pathway Is Critical for Functional Maturation of Memory CD8+ T Cells
- (2011) Weiguo Cui et al. IMMUNITY
- Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development
- (2011) Gerritje J.W. van der Windt et al. IMMUNITY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2011) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution
- (2011) M. Donia et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
- (2010) M. E. Dudley et al. CLINICAL CANCER RESEARCH
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
- (2010) M. J. Besser et al. CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation
- (2009) Alberto Mantovani et al. HUMAN IMMUNOLOGY
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- (2009) James N. Kochenderfer et al. JOURNAL OF IMMUNOTHERAPY
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
- (2008) Karl S. Peggs et al. IMMUNOLOGICAL REVIEWS
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started